VYNE news

Vyne Therapeutics Inc. announced a 1-for-50 reverse stock split and a special cash dividend of $17.3 million ahead of its pending merger with Yarrow Bioscience, facilitating the combined company's transition to the ticker YARW.

VYNE Therapeutics filed Exhibit 99.1 detailing a proposed reverse merger with Yarrow Bioscience and concurrent financing. This corporate restructuring could provide VYNE's preclinical programs with necessary capital and strategic oversight.

VYNE Therapeutics Inc. announced a special cash dividend of approximately $16.5 million, or $0.38 per share, linked to its pending acquisition by Yarrow Bioscience. The distribution is contingent on the successful completion of the transaction.

VYNE Therapeutics filed an exhibit containing a Yarrow Bioscience company overview presentation dated May 2026, indicating preparation for a proposed reverse merger transaction with concurrent financing. The filing suggests potential corporate restructuring activity that could materially impact VYNE…